FDA Opts For Education Over Registries in Proposed Opioids REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Registries could have adverse impact on patient access, notes Bob Rappaport, director of CDER's Division of Anesthesia and Analgesia Products.
You may also be interested in...
Private Grünenthal Aims For Leadership In Pain
Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.
Private Grünenthal Aims For Leadership In Pain
Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.
FDA Opioid REMS Proposal Leaves Advisory Panel Wanting More - i.e. Mandatory Training
Prior training programs have been much smaller in scope, OND Director John Jenkins points out.